Status:
ACTIVE_NOT_RECRUITING
Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure
Lead Sponsor:
St. Josefs-Hospital Wiesbaden GmbH
Conditions:
Atrial Fibrillation
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18-99 years
Brief Summary
Patients with atrial fibrillation (AF) and heart failure with reduced left ventricular ejection fraction (HFrEF) are at particularly high cardiovascular risk. Rhythm-control by means of catheter-based...
Eligibility Criteria
Inclusion
- Patients with paroxysmal or persistent AF and echocardiographically confirmed HFrEF (LVEF ≤ 40%)
- Patients who underwent their first PVI using pulsed field or cryoballoon ablation as part of clinical routine
- Patients with regular follow-up via 12-lead ECG or Holter ECG following PVI
- Patients with at least three months of follow-up
Exclusion
- Patients who did not undergo pulsed field or cryoballoon ablation for first-time PVI
- Patients with LVEF \> 40%
- Patients who declined the use of their data during initial collection
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07181291
Start Date
September 1 2025
End Date
March 31 2026
Last Update
September 18 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver General Hospital
Vancouver, British Columbia, Canada
2
Montreal Heart Institute
Montreal, Quebec, Canada
3
Vivantes Klinikum am Urban
Berlin, Germany
4
Universitätsklinikum Frankfurt am Main
Frankfurt am Main, Germany